Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DONALD L MCNEIL

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1134199300
CMS profile
452612
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$43,989.09

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DONALD L MCNEIL

NPI 1134199300 · CMS profile ID 452612

Allopathic & Osteopathic Physicians / Allergy & Immunology

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $43,989.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Octapharma USA, Inc. $96.2901/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937555481 CMS
Pharming Healthcare, Inc. $15.6801/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907877893 CMS
AstraZeneca Pharmaceuticals LP $16.1601/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914658361 CMS
Regeneron Healthcare Solutions, Inc. $16.9501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927281121 CMS
ADMA BioManufacturing LLC $13.8401/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933558305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,441.63 74
PY2020 $3,474.14 18
PY2021 $11,083.49 78
PY2022 $43,989.09 105
PY2023 $20,988.88 104
PY2024 $23,540.23 78
PY2025 $11,390.02 55

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $327,822.12 97
PY2024 Recipient $2,249.76 9
PY2024 Principal investigator $471,934.23 176
PY2023 Principal investigator $567,440.91 133
PY2022 Principal investigator $365,491.23 120
PY2021 Principal investigator $860,147.20 295
PY2020 Recipient $2,524.60 1
PY2020 Principal investigator $1,161,353.77 160
PY2019 Recipient $6,753.02 2
PY2019 Principal investigator $926,535.54 156

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,500.00 12/19/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572164
Principal investigator 1 Incyte Corporation $1,000.00 12/19/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572170
Principal investigator 1 Ionis Pharmaceuticals, Inc. $484.78 12/09/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246791197
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,693.91 12/09/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246791200
Principal investigator 1 GlaxoSmithKline, LLC. $11,665.80 11/25/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192186165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,837.80 11/25/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288753
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,630.00 11/21/2025 Non-covered Recipient Entity
Optimed Research, Limited
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235994854
Principal investigator 1 ABBVIE INC. $10,154.70 11/18/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202524489
Principal investigator 1 ABBVIE INC. $10,154.70 11/18/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202524491
Principal investigator 1 ABBVIE INC. $1,418.50 11/05/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202521329
Principal investigator 1 ABBVIE INC. $12,931.39 11/05/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202521331
Principal investigator 1 ABBVIE INC. $9,672.40 11/05/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202521333
Principal investigator 1 Ionis Pharmaceuticals, Inc. $484.78 10/14/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246789290
Principal investigator 1 ABBVIE INC. $1,051.90 10/10/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202516563
Principal investigator 1 ABBVIE INC. $1,830.60 10/10/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202516565
Principal investigator 1 ABBVIE INC. $8,818.60 10/10/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202516567
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,189.78 09/25/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190298503
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,965.23 09/15/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246787383
Principal investigator 1 Incyte Corporation $1,000.00 09/05/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572158
Principal investigator 1 ABBVIE INC. $1,179.30 09/04/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202509254
Principal investigator 1 GlaxoSmithKline, LLC. $6,840.00 09/03/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192152473
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,777.75 08/13/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185554632
Principal investigator 1 GlaxoSmithKline, LLC. $4,931.10 08/13/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192152469
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,747.80 08/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246786326
Principal investigator 1 ABBVIE INC. $419.50 08/06/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202502671
Principal investigator 1 ABBVIE INC. $5,556.00 08/06/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202502791
Principal investigator 1 ABBVIE INC. $1,189.25 08/06/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202502793
Principal investigator 1 GlaxoSmithKline, LLC. $1,875.00 08/06/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192186160
Principal investigator 1 ABBVIE INC. $240.00 07/31/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202500690
Principal investigator 1 ABBVIE INC. $10,154.70 07/25/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202499762
Principal investigator 1 ABBVIE INC. $10,154.70 07/25/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202499764
Principal investigator 1 ABBVIE INC. $10,154.70 07/25/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202499766
Principal investigator 1 GlaxoSmithKline, LLC. $8,428.00 07/23/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192186157
Principal investigator 1 ABBVIE INC. $80.00 07/18/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202498916
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,441.70 07/14/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246785255
Principal investigator 1 ABBVIE INC. $1,189.25 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202496785
Principal investigator 1 ABBVIE INC. $4,800.00 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202496787
Principal investigator 1 ABBVIE INC. $5,556.00 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202496801
Principal investigator 1 ABBVIE INC. $2,904.66 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496803
Principal investigator 1 ABBVIE INC. $6,000.00 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202496805
Principal investigator 1 ABBVIE INC. $1,179.30 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202496809
Principal investigator 1 ABBVIE INC. $600.00 07/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202496811
Principal investigator 1 Novartis Pharmaceuticals Corporation $250.50 07/01/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306985
Principal investigator 1 ABBVIE INC. $1,444.40 06/04/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202490085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223272599
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 06/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223272601
Principal investigator 1 ABBVIE INC. $2,904.66 05/08/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202484241
Principal investigator 1 ABBVIE INC. $2,470.40 05/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202482509
Principal investigator 1 ABBVIE INC. $8,013.90 05/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202482513
Principal investigator 1 GlaxoSmithKline, LLC. $646.20 04/23/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192186169
Principal investigator 1 ABBVIE INC. $2,052.30 04/04/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202474407
Principal investigator 1 ABBVIE INC. $1,444.40 04/04/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202474415
Principal investigator 1 Incyte Corporation $123.90 04/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572131
Principal investigator 1 Incyte Corporation $9.60 04/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572136
Principal investigator 1 Incyte Corporation $49.56 04/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572144
Principal investigator 1 Incyte Corporation $35.52 04/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572150
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 03/24/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223276965
Principal investigator 1 ABBVIE INC. $10,154.70 03/20/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202465191
Principal investigator 1 ABBVIE INC. $10,154.70 03/20/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202465195
Principal investigator 1 ABBVIE INC. $2,904.66 03/10/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202462208
Principal investigator 1 ABBVIE INC. $5,037.80 03/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202461032
Principal investigator 1 ABBVIE INC. $4,189.20 03/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202461036
Principal investigator 1 ABBVIE INC. $1,189.25 03/07/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202461349
Principal investigator 1 Celgene Corporation $9,202.00 03/07/2025 Non-covered Recipient Entity
Optimed Research
A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cendakimab No dispute reported 06/30/2026 1222306617
Principal investigator 1 Incyte Corporation $1.96 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572050
Principal investigator 1 Incyte Corporation $24.68 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572057
Principal investigator 1 Incyte Corporation $8.82 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572063
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572068
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572075
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572080
Principal investigator 1 Incyte Corporation $22.89 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572092
Principal investigator 1 Incyte Corporation $22.89 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572099
Principal investigator 1 Incyte Corporation $22.89 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572103
Principal investigator 1 Incyte Corporation $22.89 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572109
Principal investigator 1 Incyte Corporation $173.55 03/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572114
Principal investigator 1 Incyte Corporation $2,388.00 02/19/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572033
Principal investigator 1 ABBVIE INC. $736.00 02/14/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202451914
Principal investigator 1 ABBVIE INC. $3,188.00 02/06/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202447460
Principal investigator 1 ABBVIE INC. $1,189.25 02/06/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202447542
Principal investigator 1 GlaxoSmithKline, LLC. $2,765.70 02/03/2025 Non-covered Recipient Entity
MULTIPLE DOCTORS
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192152464
Principal investigator 1 Incyte Corporation $1,655.00 01/17/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572017
Principal investigator 1 Incyte Corporation $1,860.00 01/17/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572027
Principal investigator 1 Celgene Corporation $39,065.00 01/13/2025 Non-covered Recipient Entity
Optimed Research
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222306625
Principal investigator 1 ABBVIE INC. $2,193.30 01/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202436385
Principal investigator 1 ABBVIE INC. $2,228.60 01/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202436390
Principal investigator 1 ABBVIE INC. $489.70 01/03/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202436393
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240571996
Principal investigator 1 Incyte Corporation $7.84 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572001
Principal investigator 1 Incyte Corporation $3.84 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572007
Principal investigator 1 Incyte Corporation $19.20 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572011
Principal investigator 1 Incyte Corporation $22.08 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572023
Principal investigator 1 Incyte Corporation $99.12 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572039
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572045
Principal investigator 1 Incyte Corporation $74.34 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572086
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572119
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
OPTIMED RESEARCH LTD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240572125
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,503.75 01/01/2025 Non-covered Recipient Entity
OPTIMED RESEARCH
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190306981

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $2,000.00 1
PY2024 Value of interest $2,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 Consortium of Independent Immunology Clinics, LLC $2,000.00 $2,000.00 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147108215